Can Fite Biopharma Ltd (CANF) — Strategic Asset Allocation Index
Can Fite Biopharma Ltd (CANF) has a Strategic Asset Allocation Index of 1.8% as of June 2023. Strategic assets (PP&E of ILA123.00K plus long-term investments of ILA-) total ILA123.00K, measured against net assets of ILA6.87 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Can Fite Biopharma Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Can Fite Biopharma Ltd Strategic Asset Allocation Index (2003–2022)
This chart shows how Can Fite Biopharma Ltd's Strategic Asset Allocation Index has evolved across 18 annual periods from 2003 to 2022. As of June 2023, the index stands at 1.8%, representing strategic assets of ILA123.00K against net assets of ILA6.87 Million ILA. See Can Fite Biopharma Ltd (CANF) flexibility index to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Can Fite Biopharma Ltd (2003–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Can Fite Biopharma Ltd from 2003 to 2022, covering 18 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Can Fite Biopharma Ltd (CANF) market capitalisation.
| Year | SAAI | Strategic Assets (ILA) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 2.8% | ILA126.00K | ILA126.00K | ILA- | ILA4.47 Million | ▲ +1.5 pp |
| 2021 | 1.3% | ILA185.00K | ILA185.00K | ILA- | ILA14.38 Million | ▼ -0.7 pp |
| 2020 | 2.0% | ILA123.00K | ILA123.00K | ILA- | ILA6.07 Million | ▼ -2.8 pp |
| 2019 | 4.8% | ILA118.00K | ILA118.00K | ILA- | ILA2.44 Million | ▲ +3.3 pp |
| 2018 | 1.6% | ILA47.00K | ILA47.00K | ILA0.00 | ILA3.02 Million | ▼ -29.3 pp |
| 2017 | 30.9% | ILA942.66K | ILA28.00K | ILA914.66K | ILA3.05 Million | ▲ +29.8 pp |
| 2016 | 1.0% | ILA40.00K | ILA40.00K | ILA- | ILA3.87 Million | ▲ +0.5 pp |
| 2015 | 0.6% | ILA60.57K | ILA60.57K | ILA- | ILA10.44 Million | ▼ -1.4 pp |
| 2014 | 1.9% | ILA133.00K | ILA133.00K | ILA- | ILA6.86 Million | ▼ -1.3 pp |
| 2013 | 3.2% | ILA143.00K | ILA143.00K | ILA- | ILA4.46 Million | ▼ -5.2 pp |
| 2011 | 8.4% | ILA278.00K | ILA278.00K | ILA- | ILA3.29 Million | ▲ +4.7 pp |
| 2010 | 3.7% | ILA490.00K | ILA490.00K | ILA- | ILA13.07 Million | ▼ -1.2 pp |
| 2009 | 4.9% | ILA662.00K | ILA662.00K | ILA- | ILA13.49 Million | ▼ -2.0 pp |
| 2008 | 7.0% | ILA1.03 Million | ILA1.03 Million | ILA- | ILA14.79 Million | ▲ +3.6 pp |
| 2007 | 3.3% | ILA1.28 Million | ILA1.28 Million | ILA- | ILA38.70 Million | ▼ -0.9 pp |
| 2006 | 4.2% | ILA1.60 Million | ILA1.60 Million | ILA- | ILA38.34 Million | ▼ -0.6 pp |
| 2005 | 4.7% | ILA1.70 Million | ILA1.70 Million | ILA- | ILA35.83 Million | ▼ -27.6 pp |
| 2003 | 32.4% | ILA670.00K | ILA670.00K | ILA- | ILA2.07 Million | — |